140 related articles for article (PubMed ID: 8761363)
1. Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity.
McLeod HL; Keith WN
Br J Cancer; 1996 Aug; 74(4):508-12. PubMed ID: 8761363
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the topoisomerase I locus in human colorectal cancer.
Boonsong A; Marsh S; Rooney PH; Stevenson DA; Cassidy J; McLeod HL
Cancer Genet Cytogenet; 2000 Aug; 121(1):56-60. PubMed ID: 10958942
[TBL] [Abstract][Full Text] [Related]
3. Hyperthermic modulation of SN-38-induced topoisomerase I DNA cross-linking and SN-38 cytotoxicity through altered topoisomerase I activity.
Katschinski DM; Robins HI
Int J Cancer; 1999 Jan; 80(1):104-9. PubMed ID: 9935239
[TBL] [Abstract][Full Text] [Related]
4. CK2-mediated hyperphosphorylation of topoisomerase I targets serine 506, enhances topoisomerase I-DNA binding, and increases cellular camptothecin sensitivity.
Bandyopadhyay K; Li P; Gjerset RA
PLoS One; 2012; 7(11):e50427. PubMed ID: 23185622
[TBL] [Abstract][Full Text] [Related]
5. Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin.
Rubin E; Pantazis P; Bharti A; Toppmeyer D; Giovanella B; Kufe D
J Biol Chem; 1994 Jan; 269(4):2433-9. PubMed ID: 8300570
[TBL] [Abstract][Full Text] [Related]
6. Drug-induced down-regulation of topoisomerase I in human epidermoid cancer cells resistant to saintopin and camptothecins.
Taniguchi K; Kohno K; Kawanami K; Wada M; Kanematsu T; Kuwano M
Cancer Res; 1996 May; 56(10):2348-54. PubMed ID: 8625310
[TBL] [Abstract][Full Text] [Related]
7. Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line.
Kubota N; Kanzawa F; Nishio K; Takeda Y; Ohmori T; Fujiwara Y; Terashima Y; Saijo N
Biochem Biophys Res Commun; 1992 Oct; 188(2):571-7. PubMed ID: 1332703
[TBL] [Abstract][Full Text] [Related]
8. No alteration in DNA topoisomerase I gene related to CPT-11 resistance in human lung cancer.
Ohashi N; Fujiwara Y; Yamaoka N; Katoh O; Satow Y; Yamakido M
Jpn J Cancer Res; 1996 Dec; 87(12):1280-7. PubMed ID: 9045964
[TBL] [Abstract][Full Text] [Related]
9. MET increases the sensitivity of gefitinib-resistant cells to SN-38, an active metabolite of irinotecan, by up-regulating the topoisomerase I activity.
Sakai A; Kasahara K; Ohmori T; Kimura H; Sone T; Fujimura M; Nakao S
J Thorac Oncol; 2012 Sep; 7(9):1337-44. PubMed ID: 22722827
[TBL] [Abstract][Full Text] [Related]
10. Effect of transfection of a Drosophila topoisomerase II gene into a human brain tumour cell line intrinsically resistant to etoposide.
Asano T; Zwelling LA; An T; McWatters A; Herzog CE; Mayes J; Loughlin SM; Kleinerman ES
Br J Cancer; 1996 Jun; 73(11):1373-80. PubMed ID: 8645582
[TBL] [Abstract][Full Text] [Related]
11. Enhanced topoisomerase I activity and increased topoisomerase II alpha content in cisplatin-resistant cancer cell lines.
Minagawa Y; Kigawa J; Irie T; Kanamori Y; Itamochi H; Cheng X; Terakawa N
Jpn J Cancer Res; 1997 Dec; 88(12):1218-23. PubMed ID: 9473741
[TBL] [Abstract][Full Text] [Related]
12. [DNA topoisomerases targeting anticancer agents and mechanism for acquirement of drug resistance].
Furukawa M; Harada T; Tanaka T; Kuwano M
Nihon Rinsho; 1997 May; 55(5):1096-102. PubMed ID: 9155159
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
Liebes L; Potmesil M; Kim T; Pease D; Buckley M; Fry D; Cho J; Adler H; Dar K; Zeleniuch-Jacquotte A; Hochster H
Clin Cancer Res; 1998 Mar; 4(3):545-57. PubMed ID: 9533521
[TBL] [Abstract][Full Text] [Related]
14. DNA Topoisomerase I Gene Copy Number and mRNA Expression Assessed as Predictive Biomarkers for Adjuvant Irinotecan in Stage II/III Colon Cancer.
Nygård SB; Vainer B; Nielsen SL; Bosman F; Tejpar S; Roth A; Delorenzi M; Brünner N; Budinska E
Clin Cancer Res; 2016 Apr; 22(7):1621-31. PubMed ID: 26542057
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of topoisomerase I catalytic activity as determinant of drug response in human cancer cell lines.
Voigt W; Vanhoefer U; Yin MB; Minderman H; Schmoll HJ; Rustum YM
Anticancer Res; 1997; 17(5A):3707-11. PubMed ID: 9413228
[TBL] [Abstract][Full Text] [Related]
16. Altered expression of cell proliferation-related and interferon-stimulated genes in colon cancer cells resistant to SN38.
Gongora C; Candeil L; Vezzio N; Copois V; Denis V; Breil C; Molina F; Fraslon C; Conseiller E; Pau B; Martineau P; Del Rio M
Cancer Biol Ther; 2008 Jun; 7(6):822-32. PubMed ID: 18340113
[TBL] [Abstract][Full Text] [Related]
17. Topoisomerase-I PS506 as a Dual Function Cancer Biomarker.
Zhao M; Gjerset RA
PLoS One; 2015; 10(8):e0134929. PubMed ID: 26248194
[TBL] [Abstract][Full Text] [Related]
18. Semi-quantitative analysis of DNA topoisomerase-I mRNA level using reverse transcription-polymerase chain reaction in cancer cell lines: its relation to cytotoxicity against camptothecin derivative.
Niwa K; Misao R; Hanabayashi T; Morishita S; Murase T; Itoh M; Itoh N; Mori H; Tamaya T
Jpn J Cancer Res; 1994 Aug; 85(8):869-74. PubMed ID: 7523352
[TBL] [Abstract][Full Text] [Related]
19. The current status of camptothecin analogues as antitumor agents.
Slichenmyer WJ; Rowinsky EK; Donehower RC; Kaufmann SH
J Natl Cancer Inst; 1993 Feb; 85(4):271-91. PubMed ID: 8381186
[TBL] [Abstract][Full Text] [Related]
20. Novel missense mutation of the DNA topoisomerase I gene in SN-38-resistant DLD-1 cells.
Arakawa Y; Suzuki H; Saito S; Yamada H
Mol Cancer Ther; 2006 Mar; 5(3):502-8. PubMed ID: 16546964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
